Despite their pharmacological promise, marine-derived compounds remain largely unexplored in the context of osteoporosis therapeutics. To address this gap, the present investigation evaluated whether primary isolates sourced from the deep-marine fungus Penicillium solitum MCCC 3A00215 could stimulate osteogenesis utilizing both living subjects and controlled laboratory environments. Initial assessments revealed that bone marrow mesenchymal stem cells (BMSCs) exhibited increased osteoblastic mineralization when exposed to penicopeptide A (PPA), with the effect scaling alongside dosage; consequently, this naturally occurring peptide was advanced for comprehensive evaluation. Subsequent analyses demonstrated PPA's capacity to markedly drive BMSC lineage commitment toward osteogenesis and suppress adipocytic development, all without altering chondrogenic pathways. At the molecular level, PPA engages in direct binding with both AKT and GSK-3β, triggering their phosphorylation and ultimately driving the intracellular buildup of β-catenin. The clinical applicability of PPA was further validated using a systemic skeletal depletion model in ovariectomized female mice, where therapeutic intervention successfully preserved trabecular thickness and overall skeletal volume. Ultimately, these combined cellular and organismal findings establish PPA as a potent driver of osteoblast-mediated skeletal regeneration through the modulation of AKT, GSK-3β, and β-catenin signaling, thereby highlighting its translational promise as a preventative intervention for osteoporosis.
